A5020122083- Prostate Cancer Treatment and Research
- Metabolism, Diabetes, and Cancer
- Cancer, Hypoxia, and Metabolism
- RNA Research and Splicing
- MicroRNA in disease regulation
- Cancer, Lipids, and Metabolism
- Advanced Proteomics Techniques and Applications
- Adipose Tissue and Metabolism
- PARP inhibition in cancer therapy
- RNA modifications and cancer
- PI3K/AKT/mTOR signaling in cancer
- Advanced biosensing and bioanalysis techniques
- Cancer-related molecular mechanisms research
- Mass Spectrometry Techniques and Applications
- Ubiquitin and proteasome pathways
- DNA and Nucleic Acid Chemistry
- RNA Interference and Gene Delivery
- Cancer Cells and Metastasis
- Cancer, Stress, Anesthesia, and Immune Response
University of Cambridge
2014-2016
Cancer Research UK
2015
Cancer Research UK Cambridge Center
2014
German Cancer Research Center
2011
Heidelberg University
2011
MicroRNA-200c (miR-200c) has been shown to suppress epithelial-mesenchymal transition (EMT), which is attributed mainly targeting of ZEB1/ZEB2, repressors the cell-cell contact protein E-cadherin. Here we demonstrated that modulation miR-200c in breast cancer cells regulates cell migration, elongation, and transforming growth factor β (TGF-β)-induced stress fiber formation by impacting reorganization cytoskeleton independent ZEB/E-cadherin axis. We identified FHOD1 PPM1F, direct regulators...
Metabolic adaptation is considered an emerging hallmark of cancer, whereby cancer cells exhibit high rates glucose consumption with consequent lactate production. To ensure rapid efflux lactate, most express levels monocarboxylate transporters (MCTs), which therefore may constitute suitable therapeutic targets. The impact MCT inhibition, along the clinical altered cellular metabolism during prostate (PCa) initiation and progression, has not been described. Using a large cohort human tissues...
In a malignant tumour, cancer cells are embedded in stromal cells, namely cancer-associated fibroblasts (CAFs). These CAFs now accepted as important players dynamics, being involved tumour growth and progression. Although there various reports on the interaction between clinico-pathological significance of this cross-talk is still largely unknown. study, we aimed to characterise expression key metabolic proteins glucose transport, pyruvate/lactate shuttle system, glycolytic metabolism fatty...
Research Article5 February 2018Open Access Source DataTransparent process Identification of potential therapeutic targets in prostate cancer through a cross-species approach Sarah Jurmeister Corresponding Author [email protected] orcid.org/0000-0002-5711-1006 Uro-oncology Group, CRUK Cambridge Institute, Cambridge, UK Search for more papers by this author Antonio Ramos-Montoya Chiranjeevi Sandi Nelma Pértega-Gomes Department Medical Oncology, Dana-Farber Cancer Harvard School, Boston, MA,...
Androgen receptor (AR) signaling remains an important regulatory pathway in castrate-resistant prostate cancer, and its transcriptional downregulation could provide a new line of therapy. A number small-molecule ligands have previously demonstrated the ability to stabilize G-quadruplex structures affect gene transcription for those genes whose promoters contain quadruplex-forming sequence. Herein, we report probable formation structure present AR promoter transcriptionally location. NMR...
Metabolic alterations contribute to prostate cancer development and progression; however, the role of central metabolic regulator AMP-activated protein kinase (AMPK) remains controversial. The androgen receptor (AR), a key driver cancer, regulates cell metabolism by driving expression network genes activates AMPK through increasing one its upstream kinases. To more clearly define in we performed profiling following pharmacologic activation this kinase. We found that down-regulated upon were...
Abstract Background: An estimated 220,800 cases and 27,540 deaths from prostate cancer (PCa) will occur in the USA during 2015. Altered PI3K/AKT/mTOR signalling contributes to progression transition androgen-independent disease, for example one study reported 42% of primary 100% metastatic PCa tumours exhibited mutations, altered expression or copy number variations within this pathway. First generation mTOR inhibitors (preferentially inhibit mTORC1), have had limited anti-cancer effect...
Review on MIR200C (microRNA 200c), with data DNA, the protein encoded, and where gene is implicated.
Abstract Background: Medical therapy for men with prostate cancer (PCa) is evolving, including recent evidence to support the use of chemotherapy hormone sensitive disease. PI3K/AKT/mTOR pathway aberrations are common in patients primary PCa and almost universal metastatic tumours. The mTOR acts as a central regulator tumour cell metabolism, proliferation, cycle progression immune regulation. aim this study was investigate effects inhibitor AZD2014 on growth infiltration genetically...
This is the accepted manuscript. The final version available at http://mct.aacrjournals.org/content/14/12_Supplement_2/A123.short.